Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
As gene transfer with adeno-associated virus (AAV) vectors is starting to enter clinical practice, this review examines the impact of vector capsid choice in liver-directed gene transfer for hemophilia. Given that there are multiple clinical trials completed and ongoing in this field, it is important to review the clinical evidence, particularly as a range of AAV-vector serotypes including AAV2, AAV5, AAV8, and AAV10 have been tested. Although there have been a number of successful trials, the development of two investigational AAV vectors for hemophilia B has been discontinued because they did not meet efficacy and/or safety expectations. Whether this difference between success and failure of gene transfer approaches reflects capsid choice, vector design, manufacturing system, or other variables is a question of great interest. Here, we examine the body of evidence across trials to determine the possible influences of serotype choice on key clinical outcomes such as safety, vector clearance, treatment eligibility, occurrence of transaminase elevations, activation of capsid-directed cytotoxic T cell responses, and clinical efficacy. In summary, gene transfer requires a balance between achieving sufficient transgene expression and minimizing destructive immune responses, which may be affected by AAV-vector serotype choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 1×
“In mice, AAV serotypes 1–9 show overlapping but distinct tissue expression patterns: skeletal muscle (AAV 1–9), liver (AAV 1–3 and 5–9), heart (AAV4 and 6–9), lung (AAV4 and 6–9), brain (AAV 8–9), and testes (AAV9).(19) Notably, here are species-specific differences in AAV tropism between mice and nonhuman primates,(2…”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 3×
“Approaches to circumventing this issue include the use of alternative non-cross-reacting AAV-vector serotypes, which while demonstrated successfully with AAV5 and AAV1 in animal models33 can be challenging as NAb can cross-react across AAVvector serotypes, and immunoadsorption/plasmapheresis to reduce levels of circul…”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694 · cited 1×
“In contrast to these findings, with AAV5-based vectors, there was no observed connection between ALT or aspartate aminotransferase (AST) elevations, cytotoxic T cell responses, and reduction of factor activity (Tables 3 and 4) in clinical trials to date (0/10 participants with AAV5hFIX and 1/8 participants with AAV5hF…”
ResultHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 1×
“Interestingly, this difference does not appear to reflect the ability of the different serotypes to enter hepatocytes, but insteadmay reflectmore rapid uncoating and conversion of the singlestranded vector DNA into duplex DNA that is transcriptionally active.(27,29) In theory, a more effective vector could be administ…”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
Watakabe, A., Ohtsuka, M., Kinoshita, M., Takaji, M., Isa, K., Mizukami, H., Ozawa, K., Isa, T., & Yamamori, T. (2015) · Neuroscience Research · doi:10.1016/j.neures.2014.09.002 · Cited by 303
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301 · cited 3×
“In contrast to other AAV-vector serotypes, successful liver transduction was achieved with AAV5 vector in both NHP and humans with pre-existing anti-AAV5 NAb titers up to 1:1,030 for NHP and 1:340 for humans (Table 6).(23,45,46) Based on data such as this, gene transfer using AAV5 vectors is being investigated in part…”
ResultSelf-citationMeliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection
Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., & Daida, H. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.609-614.2005 · Cited by 246
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219 · cited 1×
“There is evidence that another TLR (TLR 2) is key for sensing AAV-vector capsid antigens.(38) As we”
BackgroundControlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131 · cited 1×
“Murine studies indicate that the development of cytotoxic T cell responses against AAV vectors requires innate immune sensing via Toll-like receptor (TLR) 9 on plasmacytoid dendritic cells.(36) TLR 9 appears to sense the vector genome, as self-complementary AAV2 vectors induced stronger TLR 9 mediated innate responses…”
BackgroundMajowicz, A., Nijmeijer, B., Lampen, M. H., Spronck, L., de Haan, M., Petry, H., van Deventer, S. J., Meyer, C., Tangelder, M., & Ferreira, V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.009 · Cited by 126 · cited 5×
“From the re-analysis of the AAV5hFIXWT trial samples, the three participants with pre-existing NAb did not experience ALT elevations and did not develop T cell responses.(45) In agreement with these data, in other human and animal trials, pre-existing immunity does not tend to be associated with subsequent T cell resp…”
BackgroundResultSelf-citationFavre, D., Provost, N., Blouin, V., Blancho, G., Chérel, Y., Salvetti, A., & Moullier, P. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0494 · Cited by 122 · cited 1×
“Indeed, in NHP, AAV-vector DNA was detected in all body fluids for up to 6 days after vector transfer, whereas complete AAV-vector particles were only detected in serum for 48–72 h post transfer.(31)”
BackgroundEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104 · cited 2×
“One study suggests, however, that memory CD8 cytotoxic T cells in AAV seropositive donor peripheral-blood mononuclear cells (PBMCs) secrete tumor necrosis factor alpha (TNF-a) in response to AAV capsid peptides rather than IFN-g.(35) Therefore, by focusing on IFN-g responses, trials may be overlooking key CD8 T cell m…”
BackgroundStructural insights into adeno-associated virus serotype 5
Govindasamy, L., DiMattia, M. A., Gurda, B. L., Halder, S., McKenna, R., Chiorini, J. A., Muzyczka, N., Zolotukhin, S., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.00867-13 · Cited by 95
Salas, D., Kwikkers, K. L., Zabaleta, N., Bazo, A., Petry, H., van Deventer, S. J., Aseguinolaza, G. G., & Ferreira, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000380 · Cited by 59
Self-citationHigh, K. A., George, L. A., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Samelson-Jones, B. J., Evans, M., Joseney-Antoine, M., Macdougall, A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-115495 · Cited by 57
Nathwani, A. C., Tuddenham, E., Chowdary, P., McIntosh, J., Lee, D., Rosales, C., Phillips, M., Pie, J., Junfang, Z., Meagher, M. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118256 · Cited by 52
Research works printed but not linked: 29
- Morrison, 2017, Landmark gene therapy poised for US approval, Nat. Rev. Drug Discov., 16, 739, 10.1038/nrd.2017.212 · doi:10.1038/nrd.2017.212
- Wang, 2010, Systematic evaluation of AAV vectors for liver directed gene transfer in murine models, Mol. Ther., 18, 118, 10.1038/mt.2009.246 · DOI · Paper page
- Greig, 2018, Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques. Hum, Gene Ther., 10.1089/hum.2018.080 · DOI
- Mitchell, 2010, AAV’s anatomy: roadmap for optimizing vectors for translational success, Curr. Gene Ther., 10, 319, 10.2174/156652310793180706 · DOI · Paper page
- Drouin, 2013, Adeno-associated virus structural biology as a tool in vector development, Future Virol., 8, 1183, 10.2217/fvl.13.112 · DOI · Paper page
- Maurer, 2018, The Assembly-Activating Protein Promotes Stability and Interactions between AAV’s Viral Proteins to Nucleate Capsid Assembly, Cell Rep., 23, 1817, 10.1016/j.celrep.2018.04.026 · DOI · Paper page
- Tseng, 2014, Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors, Front. Immunol., 5, 9, 10.3389/fimmu.2014.00009 · DOI · Paper page
- Nam, 2007, Structure of adeno-associated virus serotype 8, a gene therapy vector, J. Virol., 81, 12260, 10.1128/JVI.01304-07 · DOI · Paper page
- Srivastava, 2016, In vivo tissue-tropism of adeno-associated viral vectors, Curr. Opin. Virol., 21, 75, 10.1016/j.coviro.2016.08.003 · DOI · Paper page
- Pillay, 2017, AAV serotypes have distinctive interactions with domains of the cellular receptor AAVR, J. Virol., 10.1128/JVI.00391-17 · DOI · Paper page
- Ling, 2010, Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3, Hum. Gene Ther., 21, 1741, 10.1089/hum.2010.075 · DOI · Paper page
- Wu, 2006, Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes, J. Virol., 80, 11393, 10.1128/JVI.01288-06 · DOI · Paper page
- Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
- Davidoff, 2005, Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models, Mol. Ther., 11, 875, 10.1016/j.ymthe.2004.12.022 · DOI · Paper page
- Gao, 2006, Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates, Mol. Ther., 13, 77, 10.1016/j.ymthe.2005.08.017 · DOI · Paper page
- Salmon, 2014, Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®), Expert Rev. Clin. Pharmacol., 7, 53, 10.1586/17512433.2014.852065 · DOI · Paper page
- Rajasekaran, 2018, Infectivity of adeno-associated virus serotypes in mouse testis, BMC Biotechnol., 18, 70, 10.1186/s12896-018-0479-1 · DOI
- Majowicz, 2017, Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1, Mol. Ther., 25, 1831, 10.1016/j.ymthe.2017.05.003 · DOI · Paper page
- High, 2014, Gene therapy for hemophilia: the clot thickens, Hum. Gene Ther., 25, 915, 10.1089/hum.2014.2541 · DOI
- D’Avola, 2016, Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J. Hepatol., 65, 776, 10.1016/j.jhep.2016.05.012 · DOI · Paper page
- Majowicz, 2017, Circulating Anti-AAV5 Neutralizing Antibody Titers up to 1:1031 Do Not Affect Liver Transduction Efficacy of AAV5 Vectors in Non-Human Primates, Mol. Ther., 25, 94
- Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl. Acad. Sci. USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
- Chiorini, 1999, Cloning and characterization of adeno-associated virus type 5, J. Virol., 73, 1309, 10.1128/JVI.73.2.1309-1319.1999 · DOI · Paper page
- Akache, 2006, The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9, J. Virol., 80, 9831, 10.1128/JVI.00878-06 · DOI · Paper page
- Bell, 2012, Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid, J. Virol., 86, 7326, 10.1128/JVI.00448-12 · DOI · Paper page
- Pipe, 2017, 101HEMB01 Is a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX), Blood, 130, 3331
- Monahan, 2015, Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B, J. Thromb. Haemost., 13, 87
- Long, 2017, Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A, Blood, 130, 3332
- Calcedo, 2017, Immune Responses in 101HEMB01, a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Severe Hemophilia B, Blood, 130, 3333
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Chand, D., Mohr, F., McMillan, H., Tukov, F. F., Montgomery, K., Kleyn, A., Sun, R., Tauscher-Wisniewski, S., Kaufmann, P., & Kullak-Ublick, G. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.001 · Cited by 306
“Generation of capsid-specific T-cell responses may depend on the AAV serotype used, and the specificity of the AAV capsid variants may impact immune recognition.(10) Once a certain threshold of capsid antigen load has been reached, activation of capsid-specific T cells may result in hepatotoxicity in some cases.”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Thirteen different wild-type AAV serotypes and more than 108 capsid variants have been identified and classified [5, 6].”
BackgroundOptimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
Metadata
- Authors
- Pipe, S., Leebeek, F. W. G., Ferreira, V., Sawyer, E. K., & Pasi, J.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 15
- Pages
- 170-178
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2972588675
- Cited by
- 92
- References
- 30
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Catalyst Biosciences
- Novo Nordisk
- CSL Behring
- Shire
- Spark Therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.